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TABLE AND FIGURES LIST 
 
Table 1 Radioactive intensities that were determined at five sites of the 
rabbit’s right knee joint after the passive transdermal and 
transdermal iontophoretic administrations of [3H]-betamethasone 
sodium phosphate. 
Figure 1 Structural formula of [3H]-betamethasone sodium phosphate. 
Figure 2 Schematic diagram showing the transdermal iontophoretic system 
on a histological picture of the knee of a rabbit. 
Figure 3 Diagram showing the sites of radioactive intensity determinations in 
the right knee of a rabbit. 
Figure 4 Images of the administration side (right knee joint) of a rabbit after 
120-min passive transdermal administration. 
Figure 5 Images of the nonadministration side (left knee joint) of a rabbit 
after 120-min passive transdermal administration. 
Figure 6 Images of the administration side (right knee joint) of a rabbit after 
30-min transdermal iontophoretic administration. 
Figure 7 Images of the administration side (right knee joint) of a rabbit after 
120-min transdermal iontophoretic administration. 
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Figure 8 Images of the nonadministration side (left knee joint) of a rabbit 
after 30-min transdermal iontophoretic administration. 
Figure 9 Images of the nonadministration side (left knee joint) of a rabbit 
after 120-min transdermal iontophoretic administration. 
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ABSTRACT 
 
We used semimicro autoradiographs (ARGs) to investigate how 
tritium-labeled betamethasone sodium phosphate (beta-Na-phos) permeates 
the skin and is delivered to deeper tissues when it was transdermally 
administered to the hind knee joints of rabbits with and without iontophoresis. 
In passive transdermal administration, ARGs revealed the presence of 
beta-Na-phos only in the epidermis immediately beneath the site of drug 
administration. In active administration using iontophoresis, on the other hand, 
the plasma concentrations of beta-Na-phos after 30- and 120-min iontophoretic 
administrations were 0.090 µg eq./mL and 1.2 µg eq./mL, respectively. 
Furthermore, ARGs indicated that beta-Na-phos was ununiformly distributed 
from the skin to tissues surrounding the joint capsule (pericapsular tissues). 
The procedure suggested that beta-Na-phos reached pericapsular tissues via 
the perimysium. These results indicated the marked effect of iontophoresis to 
enhance the skin permeation of beta-Na-phos and that at least 30-min 
iontophoretic administration allowed its delivery to pericapsular tissues. 
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INTRODUCTION 
 
Glucocorticoids are drugs with the most drastic effects on rheumatoid 
arthritis and are capable of rapidly suppressing inflammation 1). 
Betamethasone and dexamethasone have potent anti-inflammatory activity 
among glucocorticoids. The esters (e.g., phosphate ester and acetate ester) of 
the drugs are used in a variety of dosage forms 2). These drugs have a 
rapid-acting profile and good efficacy, especially when given by intra-articular 
injection. However, these drugs given by intra-articular injection do not show 
long-lasting efficacy. Furthermore, it is desirable that ≥ 3-month withdrawal 
intervals be established when administering them several times 1), and 
pharmaceutical devisals are required to maintain their effects. Furthermore, 
puncture elicits concern about tissue injury and infection 3). In addition, highly 
skilled professionals are required to conduct intra-articular injection, and 
concern about the complication by infection is elicited 4). 
Iontophoresis is a method by which electrodes are placed on the skin and 
the transdermal absorption of an ionized drug is enhanced by electric repulsion 
against the electrode of the same polarity 5). Currently, the fentanyl and 
lidocaine preparations are marketed as the transdermal iontophoretic 
administration systems 6). These commercial preparations are very easy to 
administer, and the systems reduce the technical burden of professionals and 
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the psychological burden of patients 7). Rheumatoid arthritis originates from 
the inflammation of the synovial membrane. Therefore, betamethasone sodium 
phosphate (beta-Na-phos) must be delivered to the synovial membrane and 
tissues surrounding the joint capsule (pericapsular tissues). However, it is 
unknown whether a drug that was administered by iontophoresis can be 
delivered to the synovial membrane and pericapsular tissues. 
Glass et al. 8) conducted the transdermal iontophoretic administration of 
tritium-labeled dexamethasone sodium phosphate under the conditions of 0.94 
mA/cm2, 5 mA, and 20 min in a study using rhesus monkeys and reported the 
successful delivery of the drug extracted from the synovial fluid and joint 
capsule. On the other hand, Blackford et al. 9) transdermally administered 
dexamethasone sodium phosphate to the equine tibiotarsal joint at an electric 
current of 0.11 mA/cm2 which was lower than that reported by Glass et al. and 
which is accessible clinically, and reported the absence of the drug in synovial 
fluid. 
In the present study, therefore, we aimed at verifying how tritium-labeled 
beta-Na-phos, which was transdermally administered by iontophoresis, is 
delivered to the site of drug action with semimicro autoradiographs (ARGs) to 
visually validate the distribution of the drug into the hind knee joints of 
rabbits. 
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EXPERIMENTAL 
 
Materials 
6-, 21-[3H]-betamethasone 21-phosphate disodium salt (TRQ40214), 
manufactured by GE Healthcare Life Science Co., Ltd. (Tokyo, Japan), was 
purchased; its specific activity was 407 GBq (11 Ci)/mmol (Figure 1). 
Nonlabeled betamethasone 21-phosphate disodium salt (B7652-250MG) was 
purchased from Sigma Inc. (St. Louis, MO). Silver foil (99.9% in purity, 0.05 
mm in thickness, 50 mm in width) was purchased from Murata Youhaku & Co., 
Ltd. (Tokyo, Japan). Furthermore, polyvinyl alcohol (PVA; NH-17Q) was 
purchased from the Nippon Synthetic Chemical Industry Co., Ltd. (Osaka, 
Japan). Other reagents used were of special grade or equivalents and were 
standardized products for high-performance liquid chromatography (HPLC). 
Three New Zealand male albino rabbits, purchased from Kitayama Labes 
Co., Ltd. (Nagano, Japan), were used. Animals were housed in the metallic cage 
(350 mm W × 500 mm D × 400 mm H; KN-633; Natsume Seisakusho Co., Ltd., 
Tokyo, Japan) that was placed in the animal room (19.0-23.6°C in temperature; 
40.0-60.0% in humidity; ≥ 10 ventilations/h; and 12:12-h light-dark cycle). 
Animals were given a solid pellet for rabbits (LRC-4; Oriental Yeast Co., Ltd., 
Tokyo, Japan) and an appropriate volume of water. After 3-day acclimatization, 
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all the animals (2.49 kg, 2.43 kg, and 2.51 kg in body weight, respectively) were 
found healthy without showing problems and were used in the present study. 
 
Methods 
Preparation of electrode patches 
Two types of electrode patches were prepared as described below. The 
aqueous gel was poured into the support that had 1) the rectangular frame 
made of the form tape having the 3M adhesive and 2) the basement consisting 
of silver foil (anode: the reference patch) or silver chloride-coated silver foil 
(cathode: the donor patch; prepared by the application of an electric current of 
1.0 mA for 3.0 h in saline). The surface area of the gels in the patches was 484 
mm2 (22 × 22 mm). 
The reference gel was prepared with 85% (w/w) of saline and 15% (w/w) of 
PVA. This mixture was fused by heating with an autoclave at 121 °C for 20 min 
and was allowed to cool down spontaneously to room temperature before 
pouring onto the anode. The silicon-laminated polyethylene terephthalate 
(PET) film was covered onto the reference patch, and the reference patch was 
then frozen at -80°C for more than 12 h. On the other hand, the donor gel was 
prepared as described below. A solution was prepared in which 
[3H]-beta-Na-phos 18.5 MBq (500 µCi) and unlabeled beta-Na-phos were 
dissolved in ion-exchanged water. [3H]-beta-Na-phos was diluted with the 
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unlabeled beta-Na-phos solution and was then mixed with the PVA solution to 
obtain the final drug concentration of 3.3% (w/w) in the 15% (w/w) PVA solution. 
Furthermore, the silicon-laminated PET film was covered onto the donor patch 
which was then frozen at -80°C for more than 12 h. These patches were 
removed out of the freezer at 1 h before administration and were thawed 
spontaneously at room temperature before use. 
 
Passive transdermal administration 
The right and left knee joints of a rabbit were previously trimmed with an 
electric hair clipper in such a manner not to injure them. Under halothane 
anesthesia, the donor patch and the reference patch were applied to the outside 
and inside of the right knee, respectively. After the 120-min application of the 
patches, the rabbit was subjected to euthanasia by intravenously administering 
an excessive amount of sodium pentobarbital. The right and left knee joints 
extending between the middle of the femur and the shank were resected 
immediately and were then frozen with liquid nitrogen. 
 
Iontophoretic administration 
Similarly to passive transdermal administration, the donor patch and the 
reference patch were applied to the outside and inside of the right knee of 
rabbits under halothane anesthesia. A direct current source (VI 1002; Precise 
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Gauge Co., Ltd., Tokyo, Japan) was connected with the patch as illustrated in 
Figure 2, and an electric current of 0.97 mA (current density: 0.20 mA/cm2) was 
applied for 30 or 120 min. After the 30- or 120-min iontophoretic administration, 
each rabbit was subjected to euthanasia by intravenously administering an 
excessive amount of sodium pentobarbital. The right and left knee joints 
extending between the middle of the femur and the shank were resected 
immediately and were then frozen with liquid nitrogen. 
 
Plasma drug concentrations 
During iontophoretic and passive transdermal administrations, the 
heparinized syringe was used to collect approximately 0.50 mL of blood from 
the auricular vein. The blood collected was centrifuged (4.0 °C, 3000 rpm, 15 
min) to obtain plasma, and the plasma obtained was used as the specimen for 
radioactivity determination with a liquid scintillation counter (LSC-1000; 
Aloka, Tokyo, Japan). Quantification limit was set to twofold above background. 
Any value below this level was considered not detectable (ND). Plasma 
beta-Na-phos concentrations expressed as µg eq./mL were calculated from the 
measured values of radioactivity. 
 
Preparation of ARGs of the knee joints 
Regarding the right and left knee joints that were resected, the 
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carboxymethylcellulose- embedded frozen block was placed on the microtome 
(Cryomacrocut; Leica, Wetzlar, Germany) table and was fixed to allow slicing of 
the knee joint from the patellar side. The 30-µm thick sections were cut off. 
After 168-h close exposure of the section around the center of the site of patch 
application (electric current application) on the imaging plate (BAS-TR 2025 for 
3H detection; Fujifilm Corporation, Tokyo, Japan), a bioimaging analyzer (BAS 
18000; Fujifilm Corporation, Tokyo, Japan) was used to perform imaging. 
Furthermore, the histological pictures of the specimens were examined 
pathologically. The sites exposed to radiation were quantified as radioactivity 
concentration (Figure 3). 
 
Ethics rules 
The present study was conducted in compliance with "On Guideline for 
Nonclinical Pharmacokinetic Studies" (PMSB/ELD Notification No. 496 dated 
June 26, 1998). 
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RESULTS 
 
Passive transdermal administration 
Plasma concentrations of beta-Na-phos 
The plasma concentrations of beta-Na-phos after passive transdermal 
administration were measured for 120 min without electric current application. 
The plasma concentrations of beta-Na-phos were below quantification limit at 
all points for determination (30, 60, and 120 min after application). 
 
ARGs 
The ARG of the right knee joint (the joint of administration side) of a 
rabbit, which was obtained after the 120-min administration of the drug, is 
shown in Figure 4. The left image (panel a) is shown on the ARG, the middle 
image (panel b) is shown on a composite image that was obtained by 
superimposing the ARG on the histological picture, and the right image (panel 
c) is shown on the histological picture. Furthermore, radioactive intensities 
that were quantified at five sites, are shown in Table 1. The radioactive 
intensity indicating the distribution of beta-Na-phos was observed only in the 
superficial layers of the epidermis immediately beneath the site of donor patch 
administration. On the other hand, no radioactivity was observed in 
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subcutaneous tissues, i.e. muscle and bone, and in skeletal muscle-related 
tissues mainly comprising the perimysium, pericapsular membrane, and 
periosteum (Table 1). Therefore, beta-Na-phos was demonstrated not to have 
permeated subcutaneous tissues in passive transdermal administration. 
The composite image of the ARG and histological picture of the left knee 
joint (the joint of nonadministration side) is shown in Figure 5. Since the 
radioactivity intensity was of background level, the left knee joint was deemed 
not to present the distribution of beta-Na-phos. These results indicate that the 
transdermal absorbability of beta-Na-phos is very low when administered 
transdermally in a passive manner and that the drug permeates neither the 
capillaries which are present around the basal cell layer of the epidermis nor 
subcutaneous tissues. 
 
Iontophoretic administration 
Plasma concentrations of beta-Na-phos 
Plasma drug concentrations of beta-Na-phos rapidly increased from 10 
min of administration in the 120-min iontophoretic administration and 
continued to increase up to the end of the 120-min administration. The plasma 
concentration of beta-Na-phos at 120 min administration was 1.2 µg eq./mL. 
Plasma concentrations of beta-Na-phos also rapidly increased from 10 to 30 
min of administration. The plasma concentration of beta-Na-phos after 30-min 
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administration was 0.090 µg eq./mL. The profile of plasma concentrations 
confirmed the skin permeation-enhancing effect of electric current application 
as compared with passive transdermal administration. 
 
ARGs 
The composite images of the ARG and histological pictures of the right 
knee joint of rabbits at 30 and 120 min of iontophoretic administration are 
shown in Figures 6 and 7, respectively. The left images (panel a) are shown on 
the ARGs, the middle images (panel b) are shown on composite images that 
were obtained by superimposing the ARGs on histological pictures, and the 
right images (panel c) are shown on histological pictures. Furthermore, 
radioactive intensities that were quantified at five sites, are shown in Table 1. 
The administration site showed strong 3H radioactivity between the 
epidermis and the reticular dermis. Furthermore, the perimysium also showed 
radioactivity. Beta-Na-phos reached tendons, infiltrated the perimysium from 
its exterior toward its interior, and further reached the periosteum. Radioactive 
intensity was low in the periosteum and was lower in the fibrous encapsulation 
of the synovial joint and the synovial membrane which are located at deeper 
levels (Table 1). In these subcutaneous tissues, namely, radioactivity extended 
not to the area immediately beneath the administration site but in the direction 
of the tendon of joint side. The administration sitethe epidermisshowed 
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maximal radioactive intensity in the iontophoretic administration. Radioactive 
intensities were found in decreasing order of the external perimysium, internal 
perimysium, pericapsular tissues, and area close to the periosteum. The 
administration site showed a higher radioactive intensity in an animal 
receiving 30-min iontophoretic administration than in another receiving 
120-min iontophoretic administration. However, subcutaneous tissues resulted 
to show higher radioactive intensities in the animal receiving 120-min 
iontophoretic administration. 
The composite images of the ARG and histological pictures of the 
nonadministration sidethe left knee jointare shown in Figures 8 and 9. The 
radioactive intensity in the left knee joint was of background level in an animal 
receiving the 30- and 120-min iontophoretic administrations. 
These results indicated that beta-Na-phos distributed in subcutaneous 
tissues is not delivered via blood flow but is directly delivered by electric 
current application. 
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DISCUSSION 
 
Drugs permeate the skin by following the processes of dissolution and 
diffusion in the layers of the epidermis and dermis. The horny layer, that is 
located at the most external side of the skin, has a structure resembling bricks 
and mortar in which dead cells are stacked in rows and lipids connect them; it 
constitutes a barrier that does not easily permit drug permeation 10). However, 
part of the drug that was absorbed transdermally is delivered via the 
capillaries. Therefore, the bloodstream in the capillaries is considered to affect 
the amount of drug delivered to deeper tissues 11). Our results confirmed no 
radioactivity of beta-Na-phos in the plasma when passive drug administration 
was performed without electric current application, leading us to consider that 
beta-Na-phos administered by passive diffusion alone could not reach the basal 
cell layer where the capillaries are present. Therefore, our results showed that 
the distribution of beta-Na-phos as exhibited by the ARGs (Figure 4) is retained 
around the epidermal layer surface. Furthermore, the drug was not distributed 
in the left knee joint because the drug was not delivered into the capillaries. In 
general, drugs whose molecular weight exceeds 500 and ionic drugs (especially, 
anions) are considered to have low skin permeability 12). Beta-Na-phos that was 
used in the present study, has a molecular weight of 516.4 and is a monovalent 
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or bivalent anionic drug under the pH conditions of 7-8. Therefore, we consider 
that the drug has poor solubility and diffusivity to the horny layer and did not 
penetrate the capillaries. 
Beta-Na-phos could not be delivered to subcutaneous tissues even when 
performing 120-min passive transdermal administration. When performing 
30-min iontophoresis (0.20 mA/cm2), however, beta-Na-phos was distributed not 
only to the dermal layer but also to subcutaneous tissues including 
perimuscular areas; beta-Na-phos was verified also in the plasma. At this 
plasma concentration, the drug was not distributed in the left knee joint. The 
plasma concentration of beta-Na-phos was 13-fold higher after 120-min 
iontophoretic administration than after 30-min iontophoretic administration. 
However, no distribution of beta-Na-phos was found in the left knee joint after 
120-min iontophoresis. This fact leads us to consider that the distribution of 
beta-Na-phos into subcutaneous tissues at the right knee joint is not attributed 
to the systemic circulation of the drug. Based on this result, we presume that 
part of beta-Na-phos that permeated the skin by iontophoresis was 
incorporated into the capillaries and that other portions of the drug bypassing 
the capillaries were locally delivered to subcutaneous tissues beneath the site 
of drug administration. Singh et al. 13) stated that the capillary flow largely 
affects the transdermal absorption of a drug and that a drug delivered by 
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iontophoresis can bypass the capillaries. We consider that their views also 
support the delivery profile of drugs to subcutaneous tissues that was observed 
in the present study. 
Previous studies have reported the pharmacokinetics of sorts of drugs in 
the skin. In most of them, sections were prepared by slicing the skin 
horizontally to its surface; drug concentrations in each section were based to 
measure intradermal drug concentrations 14, 15, 16). Furthermore, some studies 
separately isolated and removed tissues, e.g. skin, muscle, and synovial 
membrane, after transdermal iontophoretic administration to determine tissue 
drug concentrations and reported the delivery profile of drugs by iontophoresis 
8, 17, 18). However, these reportsalthough quantitatively expressing the 
intensity of delivery to subcutaneous tissues by iontophoresisdo not clearly 
demonstrate how drugs are distributed. We prepared sections vertically to the 
joint from the skin surface in the present study and successfully clarified how 
beta-Na-phos penetrates deeper tissues from the skin surface at the time of 
iontophoresis. Beta-Na-phos in subcutaneous tissues, which had been given by 
transdermal iontophoretic administration, was extensively and horizontally 
distributed in subcutaneous tissues. In more detail, beta-Na-phos showed a 
distribution along the perimysium. Our study revealed that beta-Na-phos is 
delivered to the perimysium from its exterior toward its interior through 
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perimuscular areas. On the other hand, the intramuscular distribution of 
beta-Na-phos was not verified. Iontophoresis consists in the principle that drug 
ions move along electric current. In the body, anionic betamethasone phosphate 
competes mainly with the chlorine ion. An ionized drug functions as a main 
carrier of electric current in the absence of a competing ion. However, 
competing ions are present in the viable epidermis, dermis, and subcutaneous 
tissues. These ions are considered to reduce the amount of drugs that 
permeated 19). The ARGs revealed that beta-Na-phos is present along the 
perimysium, leading us to consider that the area includes limited amounts of 
competing ions. We presume that this bias in the distribution of competing ions 
impeded the permeation of the drug across muscles and tissues and that the 
drug permeated the tissue gaps and spaces among the perimysia and reached 
pericapsular tissues. Furthermore, beta-Na-phos further permeated along the 
perimysium when duration of iontophoretic current application was increased 
from 30 min to 120 min. Therefore, the drug was distributed not only in the 
vertical direction but also in the horizontal direction against the skin surface. 
In a study in which duration of administration is short and various kinds 
of tissues are present mixedly, therefore, concentration gradients of the drug do 
not consecutively decrease from the skin surface to subcutaneous tissues but 
the drug permeates areas, e.g., interstices between perimysia and tissues. We 
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presumed that such areas readily permit drug diffusion among tissues. 
Skin depot or reservoirsustainment of blood drug concentrations (in 
vivo) or sustainment of high fluxes (in vitro) that last for several hours after 
transdermal iontophoretic administrationhas been suggested to occur 20). 
Chaturvedula et al. 21) conducted the tape stripping method to determine the 
profile of drug concentrations at the administration site after electric current 
application and indicated that the horny layer acts as a reservoir depending on 
the physiochemical properties of a drug; furthermore, they conducted 
microdialysis and described that the dermis and subcutaneous tissues also 
include areas with high drug concentrations (depots). As indicated by ARGs 
that were taken after 30- and 120-min iontophoretic administrations (Figures 6 
and 7), we verified the relevant depots in the epidermis to areas close to 
subcutaneous tissues. Many competing ions, e.g., chloride ion (Cl-), are present 
in the dermis and subcutaneous tissues. These ions are considered to markedly 
lower the efficiency of drug permeation and to suppress drug transportation in 
the dermis and subcutaneous tissues. We estimate that the creation of such 
depots would lead to the reported prolonged increase in blood drug 
concentrations and to continual drug supply in deeper tissues. 
 
 - 18 -
CONCLUSION 
 
In conclusion, beta-Na-phos didn't penetrate subcutaneous tissues in 
passive transdermal administration, while iontophoresis successfully delivered 
beta-Na-phos to the systemic circulation and subcutaneous tissues as assessed 
by plasma drug concentrations and ARGs. Beta-Na-phos was found to have 
reached the joint capsule. Furthermore, the ARGs that were obtained after 
iontophoresis revealed the distribution of beta-Na-phos along the perimysium, 
thus verifying that beta-Na-phos is not simply diffused in vertical direction. 
The extent of beta-Na-phos distribution in vertical direction did not increase in 
parallel with the duration of iontophoresis; the extent tended to rather increase 
in horizontal (perimysial) direction. 
The present study indicated the marked effect of iontophoresis to enhance 
the skin permeation of beta-Na-phos. The 30-min transdermal iontophoretic 
administration in the present study successfully delivered beta-Na-phos to the 
joint capsule and holds promise as a novel noninvasive method for the 
treatment of rheumatoid arthritis. 
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Table 1 Radioactive intensities that were determined at five sites of the rabbit’s right knee joint after the passive 
transdermal and transdermal iontophoretic administrations of [3H]-betamethasone sodium phosphate. 
 
Radioactive intensities [(Photostimulable luminescence – background)/area] Electric 
current 
application 
Duration of 
administration Administration 
site (epidermis)
External 
perimysium 
Internal 
perimysium 
Pericapsular 
tissues 
Area close to the 
periosteum 
Absent 120 min 1.3 × 102 ND ND 9.0 × 10-2 1.0 × 10-2 
Present 30 min 1.1 × 103 5.0 × 10 1.4 × 10 4.2 × 10-1 2.2 × 10-1 
Present 120 min 8.1 × 102 4.0 × 10 1.8 × 10 4.1 × 10-1 4.4 × 10-1 
ND : Not detectable because of a value below background. 
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Figure 1 Structural formula of [3H]-betamethasone sodium phosphate. 
   : The sites of [3H]-labeling of betamethasone sodium phosphate. 
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Figure 2 Schematic diagram showing the transdermal iontophoretic system on a histological 
picture of the knee of a rabbit. 
A: Form tape, B: Sliver chloride-coated silver foil, C: Donor gel, D: Silver foil, E: Reference gel. 
a: Upper layer of the epidermis; b: Perimysium; c: Joint capsule; d: Bone; e: Bone marrow. 
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Figure 3 Diagram showing the sites of radioactive intensity determinations in the right knee of a 
rabbit. 
(a): Semimicro autoradiograph; (b): Histological picture. 
A: Administration site; B: External perimysium; C: Internal perimysium; D: Pericapsular tissues;  
E: Area close to the periosteum. 
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Figure 4 Images of the administration side (right knee joint) of a rabbit after 120-min passive 
transdermal administration. 
(a) Semimicro autoradiograph (ARG); (b) ARG + Histological picture; (c) Histological picture. 
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Figure 5 Images of the nonadministration side (left knee joint) of a rabbit after 120-min passive 
transdermal administration. 
(a): Semimicro autoradiograph; (b): Histological picture. 
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Figure 6 Images of the administration side (right knee joint) of a rabbit after 30-min transdermal 
iontophoretic administration. 
(a) Semimicro autoradiograph (ARG); (b) ARG + Histological picture; (c) Histological picture. 
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Figure 7 Images of the administration side (right knee joint) of a rabbit after 120-min transdermal 
iontophoretic administration. 
(a) Semimicro autoradiograph (ARG); (b) ARG + Histological picture; (c) Histological picture. 
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Figure 8 Images of the nonadministration side (left knee joint) of a rabbit after 30-min transdermal 
iontophoretic administration. 
(a): Semimicro autoradiograph; (b): Histological picture. 
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Figure 9 Images of the nonadministration side (left knee joint) of a rabbit after 120-min 
transdermal iontophoretic administration. 
(a): Semimicro autoradiograph; (b): Histological picture. 
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